Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tocilizumab Efficacy Across Inflammatory Subphenotypes in COVID-19-Related Acute Respiratory Distress Syndrome.

Critical care explorations - 1 Mar 2026

Filippini Daan F L, Khyali Jessica, Janssen Malou, Rademaker Emma, Cremer Olaf L, van der Poll Tom, van Amstel Rombout B E, Endeman Henrik, Bos Lieuwe D J

Abstract excerpt

OBJECTIVES: This study evaluated whether the established efficacy of tocilizumab, an interleukin-6 (IL-6) receptor antagonist, differs between the hypoinflammatory and hyperinflammatory subphenotypes. DESIGN: Retrospective analysis of data from three biobanks. SETTING: ICUs of three university teaching hospitals in the Netherlands. PATIENTS: Mechanically ventilated patients with COVID-19. INTERVENTIONS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to COVID-19 Drug Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Intensive Care Units

Share to Interleukin-6

Share to Netherlands

Share to Receptors, Interleukin-6

Share to Respiration, Artificial

Share to Respiratory Distress Syndrome

Source

Open in PubMed Open full text

Identifiers

PMID: 41837874
DOI: 10.1097/CCE.0000000000001392
PMCID: PMC12995257

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tocilizumab Efficacy Across Inflammatory Subphenotypes in COVID-19-Related Acute Respiratory Distress Syndrome.PMID 41837874Read ↗

Tocilizumab treatment leads to early resolution of lymphopenia and myeloid dysregulation in patients hospitalized with COVID-19Semantic proximity Read ↗

Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 prospective phase 2 trialSemantic proximity Read ↗

Timely Administration of Tocilizumab Improves Survival of Hospitalized COVID-19 PatientsSemantic proximity Read ↗

Temporal stability of inflammatory subphenotypes of acute respiratory distress syndrome: 28-day insights from the ICAR trial.Semantic proximity Read ↗

A systematic review and meta-analysis of Anakinra, Sarilumab, Siltuximab and Tocilizumab for Covid-19Semantic proximity Read ↗

Bedside identification of subphenotypes in acute respiratory failure (PHIND): a multicentre, observational cohort study.Semantic proximity Read ↗

A two-arm, randomized, controlled, multi-centric, open-label Phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19Semantic proximity Read ↗

Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: a retrospective cohort studySemantic proximity Read ↗

Patient phenotypes and their relation to TNFα signaling and immune cell composition in critical illness and autoimmune diseaseSemantic proximity Read ↗

Inflammatory phenotyping predicts clinical outcome in COVID-19.Semantic proximity Read ↗

Clinical outcomes of immunomodulation therapy in immunocompromised patients with severe Covid-19 and high oxygen requirementSemantic proximity Read ↗

Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: a prospective observational study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.